‘There was a catch’: My doctor friend was outraged by his hospital’s fundraising tactics. Where do we draw the line?
THE SO WHAT
Using the doctor–patient trust channel for hospital fundraising blurs ethical and operational lines in healthcare. Operators in regulated, high-trust domains should expect similar scrutiny on any monetization that piggybacks on core relationships — document where you draw the line before a story like this forces it for you.
READ THE SOURCE
MORE FROM THE WIRE
Tech & InnovationMeta reportedly wants to start a cloud computing business to compete with AWS, Azure and others
If Meta really spins up a Meta Compute unit to sell excess capacity to other hyperscalers and startups, GPU supply becomes less of a moat and more of a trading asset between giants. For operators, this could mean more leverage on price and availability in 2026–2027, but also more dependency on a social platform’s infra roadmap.
Tech & InnovationTesla saw a massive sales jump in the second quarter
Tesla moving 480,000+ EVs on the back of cheaper trims is a reminder that price and distribution still beat novelty in this market. If you’re building in EV or charging, plan around a world where the installed base skews toward cost-optimized, mass-market hardware, not premium early adopters.
Tech & InnovationSmall business group challenges brokers’ request for FMCSA standard
Regulatory fights between small carriers and brokers over FMCSA standards are a reminder that logistics data and control layers are politically contested, not just technically determined. If you’re building freight tech, bake regulatory volatility into your product roadmap and avoid over-optimizing for one side’s preferred rules.
Tech & InnovationRivian raises EV sales forecast as Q2 production ramps up
Rivian nudging its 2026 shipment forecast up after launching the R2 SUV is less about one model and more about proving it can scale beyond niche volumes. Suppliers and partners should treat this as a signal that Rivian is moving into “reliable counterparty” territory — but still price in ramp risk.